Invested in Sustainable Value Creation

Wavelength’s Operating Executives specialize in the
nexus of Lifesciences, Healthcare, and Technology.

We focus on delivering sustainable value...
not on account development.

Expertise Bound With Long Term Perspective

Wavelength’s Operating Executives specialize in the nexus of Lifesciences, Healthcare, and Technology. We deliver transformations resulting in sustainable business value.

We solve complex problems with small teams possessing deep industry expertise. Rolling up our sleeves, we get our hands dirty and work quickly to distill and resolve your needs - driven by an energy and passion for great results. You can count on us to introduce fresh, sound ideas tempered by an experience-tested dose of realism. We always align with our business partners through shared interests.

Our approach will be most refreshing if you’ve ever been oversupplied with high dollar, marginal talent, sold work that didn’t move the needle on the business, or received a strategic plan filled with bright, but flawed and non-implementable ideas.

We’ve held many roles - executives, entrepreneurs, and consultants. These experiences mean we have seen numerous scenarios from multiple viewpoints. You will never have to question our loyalty. When you partner with us, it’s your agenda, period.

If all this resonates with you, then we are

... on your Wavelength

Global News in Lifesciences, Healthcare, and Technology

SOPHiA GENETICS Raises $110 Million in Oversubscribed New Funding Round

Supporting the Company's Global Expansion to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine SOPHiA GENETICS enters next stage of its global expansion with oversubscribed Series F round exceeding $110 million, led by major health-tec...
Biopharmaceuticals, Venture Capital
SOPHiA GENETICS

Comcast xFi Advanced Gateway Modem/Router

Here is Comcast?s most advanced modem/router which promises speed as well as ease of use.

FDA Grants Fast Track Status to Aegle Therapeutics' AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa

BOSTON and MIAMI, Oct. 1, 2020 -- (Healthcare Sales & Marketing Network) -- Aegle Therapeutics Corporation today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102 for the treatment of patients with dyst...
Biopharmaceuticals, Dermatology, FDA
Aegle Therapeutics, Dystrophic Epidermolysis Bullosa

Harman Kardon ? Home Speaker with Cortana

Here is a premium home speaker with superior sound coupled with Microsoft?s Cortana